Agios Pharmaceuticals receives FDA approval for AQVESME (mitapivat) to treat anemia in thalassemia patients, shares rise by over 18%. The company targets a launch population of 4,000 patients in the U.S. with a price of $425,000 per year. Potential peak-year-sales across multiple indications are estimated at $1 billion.

Mitapivat addresses the mechanism within red blood cells to strengthen and prolong their lifespan, reducing fatigue and transfusion dependency in thalassemia patients. The rare blood disorder causes low hemoglobin levels, leading to weakness and fatigue. Agios Pharmaceuticals aims to cater to a niche market with significant unmet medical needs.

Following a positive FDA approval for mitapivat in thalassemia, Agios Pharmaceuticals is set to rebound from a previous setback in a sickle cell disease trial. The company expects rapid sales expansion with the introduction of the new indication. Consideration for investment in the stock should account for recent developments and market potential.

For investors considering Agios Pharmaceuticals stock, the Motley Fool recommends exploring alternative investment options. The company did not make the list of top 10 stocks for potential high returns. The advisory team emphasizes historical returns and market outperformance, offering insights for individual investors’ decision-making processes.

Read more at Yahoo Finance: Here’s Why Shares in Agios Pharmaceuticals Popped Today